George Clinical Chosen As CRO For Hummingbird Bioscience's Phase 1 Oncology Trials

KUALA LUMPUR, May 5 (Bernama) -- George Clinical has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy programme targeting HER3, a potent driver of tumour growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer.

According to a statement, George Clinical is providing its full-service clinical research organisation (CRO) expertise for the Hummingbird Bioscience-sponsored trials.

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing biologic medicines for hard-to-treat diseases, is bringing its clinical-stage anti-HER3 drug known as HMBD-001 into molecular-matched patient trials in Australia for the first time.

Early phase clinical trials are primarily designed to evaluate the safety and tolerability of a new therapy as well as to identify a suitable dose for further evaluation.

However, historically any preliminary efficacy data generated has been considered only as suggestive and requires further exploration in larger later phase trials.

As molecular-based therapies have evolved, it is common to see significant antitumour activity when targeted agents are tested on molecularly selected populations in early drug development.

Signaling pathways and molecular networks are known for their critical roles in driving and controlling cellular processes and are therefore linked to the onset of cancer, as well as its potential treatment.

The development of agents targeting these pathways and networks is a key piece in the ongoing advancement of molecular-matched therapy and its advancement to provide better patient outcomes.

Coupled with its experience in conducting over 300 oncology studies globally, as well as its established robust network of practicing medical oncologists with expertise across a range of tumour types and the latest immunotherapies, George Clinical has a deep and well-regarded history in the conduct of early phase studies.

Using the combination of scientific leadership and local knowledge, the oncology trials conducted by George Clinical maintain their focus on the trials’ scientific objective while maximising trial conduct expertise to enable the best result possible.

-- BERNAMA